Surufatinib: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01489-y
Abstract: Surufatinib (Sulanda®), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30… read more here.
Keywords: first approval; extrapancreatic net; surufatinib first; surufatinib ... See more keywords
Efficacy and toxicity of surufatinib in neuroendocrine tumors: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13149
Abstract: The incidence and prevalence of neuroendocrine neoplasms (NENs) has increased in the US in recent decades. These are well‐vascularized tumors, but no antiangiogenic drug has been approved for treatment of extra‐pancreatic NENs. The aim is… read more here.
Keywords: efficacy; surufatinib; efficacy toxicity; meta analysis ... See more keywords
Abstract 1043: Efficacy and mechanistic insights of Shengyang Qushi Decoction in managing surufatinib-associated diarrhea
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-1043
Abstract: Surufatinib, a novel TKI targeting VEGFRs, FGFR1, and CSF1R, treats advanced neuroendocrine tumors but often causes diarrhea, which impairs patients’ health and anti-tumor efficacy. We’ve successfully established a rat model of surufatinib-induced diarrhea. This study… read more here.
Keywords: decoction; control; group; dose decoction ... See more keywords
Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4111
Abstract: 4111 Background: In the phase 3 SANET-p trial (NCT02589821), surufatinib significantly increased progression-free survival (PFS) compared with placebo in patients with progressive, well-differentiated (grade 1 or 2), advanced pancreatic neuroendocrine tumors (NETs). Here we report… read more here.
Keywords: well differentiated; surufatinib; placebo; baseline cga ... See more keywords
Surufatinib combined with locoregional therapies and immune checkpoint inhibitor (ICI) for treating unresectable or metastatic intrahepatic cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.4_suppl.593
Abstract: 593 Background: Advanced metastatic ICC, characterized by poor survival and limited therapeutic options, may benefit from the combined use of surufatinib—a selective tyrosine kinase inhibitor targeting VEGFR 1, 2, and 3, FGFR1, and CSF-1R—and ICIs,… read more here.
Keywords: locoregional therapies; tace; metastatic intrahepatic; inhibitor ... See more keywords
Case report: Remarkable response to later-line surufatinib in an adult patient with liver metastatic of pancreatoblastoma
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1361628
Abstract: Pancreatoblastoma (PB), a neoplasm derived from pancreatic follicular cells, primarily affects the pediatric population. Although infrequent in adults, it is associated with a considerably worse prognosis. Approximately one-third of patients are diagnosed with metastatic disease,… read more here.
Keywords: pancreatoblastoma; liver metastatic; surufatinib; case report ... See more keywords
Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Diagnostic and Interventional Radiology"
DOI: 10.4274/dir.2024.242673
Abstract: PURPOSE The aim of the present study is to report the clinical results of patients with advanced intrahepatic cholangiocarcinoma (ICC) who received combination therapy of hepatic arterial infusion chemotherapy (HAIC), toripalimab and surufatinib. METHODS The… read more here.
Keywords: hepatic arterial; treatment; advanced intrahepatic; intrahepatic cholangiocarcinoma ... See more keywords
PROTAC-Surufatinib Suppresses Pancreatic Neuroendocrine Neoplasms Progression by Inducing Ferroptosis through Inhibiting WNT/β-catenin Pathway Mediated by HMOX1
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.106357
Abstract: The small-molecule targeting drug Surufatinib is a new strategy for pancreatic neuroendocrine neoplasms (pNENs). However, the adverse reactions of Surufatinib should not be ignored in clinical practice. Based on PROTAC technology, we developed a novel… read more here.
Keywords: progression; inducing ferroptosis; hmox1; wnt catenin ... See more keywords